To amplify the FLT3-ITD juxtamembrane domain, the following primer pair was used: forward – 5′-TGTCGAGCAGTACTCTAAACATG-3′, reverse – 5′-CTTTCAGCATTTTGACGGCAACC-3′. Granulocyte ...

AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。

Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

The first patient has been dosed in the QuANTUM-Wild phase 3 trial evaluating Daiichi Sankyo’s Vanflyta (quizartinib) in combination with standard intensive induction and consolidation chemotherapy ...

“We know how important MRD detection is, and will continue to be, in AML” said Adrian Smith, CEO, OGT. “Advances in the understanding of AML MRD, such as recent research studies highlighting the ...

In the Blood Cancer Journal study, blocking this protein treats a specific form of AML called FLT3-ITD AML that develops directly—without an MPN developing first. This type of AML can be treated ...

The National Health Service (NHS) England has announced the routine commissioning of Daiichi Sankyo's quizartinib for acute ...

NICE has recommended Vanflyta (quizartinib) for routine NHS commissioning as an induction, consolidation, and maintenance therapy for treating newly diagnosed FLT3-ITD-positive AML, an indication ...

It has been approved for the treatment of newly diagnosed (FLT3-ITD-positive) acute myeloid leukaemia on the NHS in Scotland. Acute myeloid leukaemia is a fast-growing type of blood cancer that ...